首页> 美国卫生研究院文献>PLoS Pathogens >Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
【2h】

Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge

机译:口服脊髓灰质炎病毒挑战后口服和灭活脊髓灰质炎病毒疫苗针对病毒脱落引起的粘膜免疫系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inactivated poliovirus vaccine (IPV) may be used in mass vaccination campaigns during the final stages of polio eradication. It is also likely to be adopted by many countries following the coordinated global cessation of vaccination with oral poliovirus vaccine (OPV) after eradication. The success of IPV in the control of poliomyelitis outbreaks will depend on the degree of nasopharyngeal and intestinal mucosal immunity induced against poliovirus infection. We performed a systematic review of studies published through May 2011 that recorded the prevalence of poliovirus shedding in stool samples or nasopharyngeal secretions collected 5–30 days after a “challenge” dose of OPV. Studies were combined in a meta-analysis of the odds of shedding among children vaccinated according to IPV, OPV, and combination schedules. We identified 31 studies of shedding in stool and four in nasopharyngeal samples that met the inclusion criteria. Individuals vaccinated with OPV were protected against infection and shedding of poliovirus in stool samples collected after challenge compared with unvaccinated individuals (summary odds ratio [OR] for shedding 0.13 (95% confidence interval [CI] 0.08–0.24)). In contrast, IPV provided no protection against shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59–1.11]) or when given in addition to OPV, compared with individuals given OPV alone (summary OR 1.14 [95% CI 0.82–1.58]). There were insufficient studies of nasopharyngeal shedding to draw a conclusion. IPV does not induce sufficient intestinal mucosal immunity to reduce the prevalence of fecal poliovirus shedding after challenge, although there was some evidence that it can reduce the quantity of virus shed. The impact of IPV on poliovirus transmission in countries where fecal-oral spread is common is unknown but is likely to be limited compared with OPV.
机译:在消灭脊髓灰质炎的最后阶段,灭活的脊髓灰质炎病毒疫苗(IPV)可用于大规模疫苗接种运动。在根除后全球协调停止口服脊髓灰质炎病毒疫苗(OPV)疫苗接种之后,许多国家也可能会采用该疫苗。 IPV在控制脊髓灰质炎暴发中的成功将取决于针对脊髓灰质炎病毒感染诱发的鼻咽和肠粘膜免疫程度。我们对截至2011年5月发表的研究进行了系统的综述,记录了在“挑战”剂量的OPV后5-30天收集的粪便样本或鼻咽分泌物中脊髓灰质炎病毒的脱落率。对根据IPV,OPV和组合时间表进行疫苗接种的儿童的流失几率的荟萃分析对研究进行了合并。我们确定了31项符合入选标准的粪便脱落研究和4项鼻咽样本脱落研究。与未接种疫苗的个体相比,接种过OPV疫苗的个体在攻击后收集的粪便样本中可免受感染和脊髓灰质炎病毒的脱落(脱落的总比值比[OR]为0.13(95%置信区间[CI] 0.08-0.24))。相比之下,与未接种疫苗的个体(摘要或0.81 [95%CI 0.59–1.11])或与OPV联合使用时相比,IPV没有提供防止脱落的保护措施,而与仅接受OPV的个体相比(摘要或1.14 [95%CI 0.82–95] 1.58])。鼻咽脱落的研究不足以得出结论。 IPV不能诱导足够的肠道粘膜免疫力来降低攻毒后粪便脊髓灰质炎病毒脱落的发生率,尽管有证据表明它可以减少病毒的散播量。在粪便口传播普遍的国家,IPV对脊髓灰质炎病毒传播的影响尚不明确,但与OPV相比可能受到限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号